Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients

Sigalotti, L and Fratta, E and Bidoli, E and Covre, A and Parisi, G and Colizzi, F and Coral, S and Massarut, S and Kirkwood, JM and Maio, M (2011) Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. Journal of Translational Medicine, 9.

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (914kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

Background: The prognosis of cutaneous melanoma (CM) differs for patients with identical clinico-pathological stage, and no molecular markers discriminating the prognosis of stage III individuals have been established. Genome-wide alterations in DNA methylation are a common event in cancer. This study aimed to define the prognostic value of genomic DNA methylation levels in stage III CM patients.Methods: Overall level of genomic DNA methylation was measured using bisulfite pyrosequencing at three CpG sites (CpG1, CpG2, CpG3) of the Long Interspersed Nucleotide Element-1 (LINE-1) sequences in short-term CM cultures from 42 stage IIIC patients. The impact of LINE-1 methylation on overall survival (OS) was assessed using Cox regression and Kaplan-Meier analysis.Results: Hypomethylation (i.e., methylation below median) at CpG2 and CpG3 sites significantly associated with improved prognosis of CM, CpG3 showing the strongest association. Patients with hypomethylated CpG3 had increased OS (P = 0.01, log-rank = 6.39) by Kaplan-Meyer analysis. Median OS of patients with hypomethylated or hypermethylated CpG3 were 31.9 and 11.5 months, respectively. The 5 year OS for patients with hypomethylated CpG3 was 48% compared to 7% for patients with hypermethylated sequences. Among the variables examined by Cox regression analysis, LINE-1 methylation at CpG2 and CpG3 was the only predictor of OS (Hazard Ratio = 2.63, for hypermethylated CpG3; 95% Confidence Interval: 1.21-5.69; P = 0.01).Conclusion: LINE-1 methylation is identified as a molecular marker of prognosis for CM patients in stage IIIC. Evaluation of LINE-1 promises to represent a key tool for driving the most appropriate clinical management of stage III CM patients. © 2011 Sigalotti et al; licensee BioMed Central Ltd.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Sigalotti, L
Fratta, E
Bidoli, E
Covre, A
Parisi, G
Colizzi, F
Coral, S
Massarut, S
Kirkwood, JMkirkwood@pitt.eduKIRKWOOD
Maio, M
Date: 26 May 2011
Date Type: Publication
Journal or Publication Title: Journal of Translational Medicine
Volume: 9
DOI or Unique Handle: 10.1186/1479-5876-9-78
Schools and Programs: School of Medicine > Medicine
Refereed: Yes
Date Deposited: 28 Oct 2016 18:48
Last Modified: 01 Nov 2017 12:56
URI: http://d-scholarship.pitt.edu/id/eprint/30057

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item